Oppenheimer Holdings, Inc. reiterated their buy rating on shares of United Therapeutics Corporation (NASDAQ:UTHR) in a report issued on Tuesday.

A number of other equities analysts have also weighed in on UTHR. Zacks Investment Research lowered United Therapeutics Corporation from a buy rating to a hold rating in a research note on Thursday, October 20th. Ladenburg Thalmann Financial Services upgraded United Therapeutics Corporation from a neutral rating to a buy rating and lifted their price objective for the company from $128.00 to $138.00 in a research note on Friday, October 28th. Cowen and Company set a $144.00 price objective on United Therapeutics Corporation and gave the company a buy rating in a research note on Thursday, October 27th. Wedbush reiterated an outperform rating and set a $229.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, November 4th. Finally, Barclays PLC lowered United Therapeutics Corporation from an equal weight rating to an underweight rating and reduced their price objective for the company from $115.00 to $100.00 in a research note on Tuesday, November 29th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. United Therapeutics Corporation presently has a consensus rating of Hold and an average target price of $136.42.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 168.42 on Tuesday. The company has a market capitalization of $7.14 billion, a price-to-earnings ratio of 11.40 and a beta of 1.42. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $168.82. The company’s 50-day moving average price is $156.15 and its 200-day moving average price is $133.21.

This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be viewed at http://www.watchlistnews.com/united-therapeutics-corporations-uthr-buy-rating-reiterated-at-oppenheimer-holdings-inc/1121804.html.

In related news, CEO Martine A. Rothblatt sold 1,208 shares of United Therapeutics Corporation stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $145.73, for a total value of $176,041.84. Following the completion of the transaction, the chief executive officer now owns 1,348 shares in the company, valued at approximately $196,444.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,233 shares of United Therapeutics Corporation stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $132.81, for a total value of $163,754.73. Following the completion of the transaction, the chief executive officer now owns 1,373 shares of the company’s stock, valued at approximately $182,348.13. The disclosure for this sale can be found here. In the last 90 days, insiders sold 19,778 shares of company stock valued at $2,728,567. 7.50% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the company. Fisher Asset Management LLC boosted its stake in United Therapeutics Corporation by 1.0% in the third quarter. Fisher Asset Management LLC now owns 3,124 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 32 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in United Therapeutics Corporation by 0.6% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,373 shares of the biotechnology company’s stock valued at $753,000 after buying an additional 35 shares during the last quarter. Sumitomo Mitsui Asset Management Company LTD boosted its stake in United Therapeutics Corporation by 1.6% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 3,194 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 50 shares during the last quarter. First Citizens Bank & Trust Co. boosted its stake in United Therapeutics Corporation by 1.4% in the third quarter. First Citizens Bank & Trust Co. now owns 3,684 shares of the biotechnology company’s stock valued at $435,000 after buying an additional 50 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares during the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.